AKYA - Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023 | Benzinga
Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale
Global network of CROs providing Akoya's spatial phenotyping solutions will also exhibit at SITC
MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (NASDAQ:AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023.
At booth #719, Akoya Biosciences will highlight its new PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platforms, which offer significant advancements in speed and scale for spatial biology research.
- PhenoCycler-Fusion 2.0: Features multi-slide automation, enabling researchers to generate ultrahigh-plex spatial phenotyping data for larger and more complex samples at unprecedented speed.
- PhenoImager HT 2.0: Features onboard spectral unmixing, which accelerates biomarker development and validation workflows.
"We continue to evolve our spatial biology platforms to enable even greater speed and scale, which is essential for our customers as they discover and validate new biomarkers," said Brian McKelligon, CEO of Akoya Biosciences. "We're excited to be at SITC where we will highlight these innovations and share an extensive array of new spatial phenotyping data. Many members of our global network of CRO service providers will also be at SITC. These organizations are a critical resource for biopharmaceutical companies as the industry continues to integrate spatial biology into their discovery and translational workflows."
Ultrahigh-plex Spatial Phenotyping Reveals Markers Associated with Response to Immunotherapy
Among the posters being presented at SITC is one describing the spatial tumor microenvironment landscapes of cutaneous squamous cell carcinoma (cSCC) tissues from patients over the course of immunotherapy treatment. An ultrahigh-plex antibody panel encompassing cell lineages, activation states, immune checkpoints, structural and metabolic markers was deployed on the PhenoCycler-Fusion platform for analysis of the tissue microenvironment. Cellular phenotypes, spatial neighborhoods and functional states driving tumor pathogenesis and response to immunotherapy were identified. The poster will be presented by Arutha Kulasinghe, Ph.D., leader of the Clinical-oMx Group at the Frazer Institute of the University of Queensland, Australia, and founding scientific director of the Queensland Spatial Biology Centre.
Dr. Kulasinghe, his colleagues, and Akoya collaborators recently published a peer-reviewed article describing another ultrahigh-plex spatial biology study that revealed ...